Life Sciences & Lab Space Litigation
The post-pandemic lab-space boom left a market that still needs 20 to 25 million square feet of net absorption or supply reduction to reach equilibrium — and the funding crunch behind much of that oversupply is now generating its own disputes.
What's driving disputes right now
Grounded in current market and legal reporting, not speculation — each item links to its source.
A 200M+ SF Market Still Working Off Oversupply
The U.S. lab market needs roughly 20 to 25 million square feet of net absorption or supply reduction to return to equilibrium. A lender has now moved to foreclose on Harlem's ~$700 million Taystee Lab Building — an 11-story, ~350,000-sq-ft purpose-built lab tower that has not signed a single lab lease in the four years since it opened.
Why it matters: A flagship lab tower going to foreclosure with zero leases signed is a stark, concrete measure of how severe the demand collapse has become for lenders and developers eyeing new ground-up lab construction.
Conversion Out of Lab Inventory
Over 6.2 million square feet of lab space has already exited the inventory for other uses. Owners without scale or experience face rising odds of distress over the next 12 to 24 months as this repositioning continues.
Capital-Call and Funding-Contingent Lease Disputes
A Chicago dispute — Portal Innovations v. Beacon Capital Partners — centers on missed capital calls tied to a shared lab space venture that could leave the tenant unable to meet its lease obligations. As funding tightens across the sector, this fact pattern is likely to recur.
Lab Build-Out and TI Disputes
Lab-specific tenant improvements — fume hoods, specialized HVAC, vibration control — are expensive and heavily disputed on default or exit, more so than typical office TI.
Capital-Constrained Tenants Seeking Steep Lease Buyouts
Biopharma tenant Werewolf Therapeutics reportedly offered its landlord, an Alexandria Real Estate Equities affiliate, only about 10 cents on the dollar to buy out its remaining lab lease in Watertown, MA — the parties ultimately settled on an accelerated termination roughly four years early, with a $2.7 million total settlement payment.
Why it matters: A real, documented benchmark for how capital-constrained biotech tenants are negotiating early lease exits — useful reference data for any lab landlord facing a similar buyout request.
Landlords Pursuing Flex-Lab Operators for Nonpayment
BioMed Realty, Blackstone's life-sciences REIT arm, sued flexible lab-space operator SmartLabs over roughly $885,000 in unpaid rent plus nearly $2 million in default fees at a Cambridge, MA property, alleging SmartLabs moved money among affiliated entities without regard to corporate formalities — a similar prior dispute is alleged at a SmartLabs San Francisco site.
Why it matters: A major life-sciences landlord pursuing a flex-lab operator for payment defaults is a template for how landlords may respond to tenant financial strain across their broader lab portfolios.
Facing an issue like this?
If your portfolio has exposure here, it's worth a conversation before it becomes a bigger problem.
View Lease Dispute matters → · View Construction Defect matters → · All property types →